Please sign in to follow a disease.
New lubricant injection could ease arthritic knee pain
NCT ID NCT05771948
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new injectable lubricant called CCoat for people with mild to moderate knee osteoarthritis. 125 participants received either a single injection of CCoat or a placebo and were followed for six months. The goal was to see if CCoat safely reduces pain and improves knee function better than placebo.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CCoat (a liposomal joint lubricant injected into the knee)
- What this could lead to
- If it works, this could offer a new, non-surgical option to reduce pain and improve knee function in people with mild to moderate osteoarthritis.
- What could go wrong
- This is a small, early-stage trial with no phase designation. The treatment may not outperform placebo, and benefits may be modest or temporary. Joint injections carry risks like infection or pain at the injection site.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
125 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
Jun 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subject has signed and dated the informed consent form 2. Age ≥30 and ≤ 85 years old 3. Pain in the intended study knee with an average VAS score (active) of ≥3 over the last week before screening. 4. Degenerative changes in the intended study knee that can be categorized as grade I -III- Kellgren Lawrence based upon standing anterior- posterior and lateral radiographsof the knee 5. Body Mass Index (BMI) between 18.5 and 38 6. A negative urine pregnancy test female patient with childbearing potential at Visit 1 prior to intra-articular injection of AqueousJoint. 7. If female, the subject must be either postmenopausal, OR permanently surgically sterile OR for women of childbearing potential using at least 2 methods of birth control that are effective from at least 30 days before Visit 1 through visit 26w (26 weeks post injection). 8. Are willing or able to comply with procedures required in this protocol. Exclusion Criteria: 1. Osteoarthritis of the index knee graded 4 according to the Kellgren-Lawrence Grading 2. History of significant knee trauma or previous surgery of the intended study knee within the last 3 months preceding the screening 3. Pain in both knees with a VAS score of ≥5 4. Intra-articular injection to the intended study knee within 3 months before Screening 5. Significant instability of the index knee 6. Malalignment more than 10 degrees varus OR 10 degrees valgus according to standing X-ray 7. Intake of chronic pain medications (especially opioid pain relievers) without an option to pause for the period of the study 8. History of Psoriatic Arthritis, Rheumatoid Arthritis, or any other inflammatory condition associated with arthritis 9. Wound in the area of the intended study knee 10. Any known tumor of the index knee 11. Any known history of intra-articular or osseous infection of the index knee 12. Any evidence of active infection anywhere in the body. Urinary Tract Infection (UTI) patients can be included following antibiotic treatment, provided that two consecutive cultures are negative (taken within at least 2 weeks of each other) 13. Any known history of inflammatory arthropathy or crystal-deposition arthropathy 14. Any known systemic cartilage and/or bone disorder, such as but not limited to, chondrodysplasia or osteogenesis imperfecta 15. Body Mass Index (BMI) \> 38 16. Active malignances, excluding BCC. 17. Chemotherapy and/or radiation in the past 12 months 18. Known history of a severe allergic reaction 19. Patient who is pregnant or intends to become pregnant during the study 20. History of any significant systemic disease, such as but not limited to: HIV, hepatitis, HTLV, syphilis, and coagulopathies 21. A Known substance or alcohol abuse 22. Participation in other clinical trials within 60 days to before the study or concurrent with the study 23. Known insulin dependent diabetes mellitus 24. Unable to undergo X-ray
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Knee osteoarthritis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assuta
Ashdod, Israel
-
Kaplan Medical Center
Rehovot, Israel
-
Sheba Medical Center
Ramat Gan, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Custom knee guides put to the test in obese patients
- Can a shot of your own blood ease arthritic knees?
- 5,000 knee arthritis patients tracked to crack the treatment code
- Can a hydrogel injection ease knee arthritis pain?
- Weekly shot aims to melt away pounds in obesity fight
- Can shockwave plus injections quiet knee arthritis pain?